{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:13:49Z","timestamp":1789910029417,"version":"4.0.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T00:00:00Z","timestamp":1520035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","award":["5R24TW008886"],"award-info":[{"award-number":["5R24TW008886"]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,16]]},"DOI":"10.1093\/cid\/ciy179","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T08:22:10Z","timestamp":1519892530000},"page":"708-716","source":"Crossref","is-referenced-by-count":46,"title":["Delayed Sputum Culture Conversion in Tuberculosis\u2013Human Immunodeficiency Virus\u2013Coinfected Patients With Low Isoniazid and Rifampicin Concentrations"],"prefix":"10.1093","volume":"67","author":[{"given":"Christine","family":"Sekaggya-Wiltshire","sequence":"first","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrei","family":"von Braun","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Ledergerber","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Buzibye","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Henning","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland"},{"name":"Division of Tropical Health and Medicine, James Cook University, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Musaazi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Gutteck","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min\u00e9","family":"de Kock","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jetter","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Byakika-Kibwika","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"},{"name":"School of Medicine, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Eberhard","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Matovu","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Joloba","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari C","family":"Manabe","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses R","family":"Kamya","sequence":"additional","affiliation":[{"name":"School of Medicine, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascia","family":"Corti","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kambugu","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan S","family":"Fehr","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland"},{"name":"Department of Public Health at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,3]]},"reference":[{"key":"key\n\t\t\t\t20180821093403_CIT0001","author":"World Health Organization"},{"key":"key\n\t\t\t\t20180821093403_CIT0002","volume-title":"Prevalence and factors associated with non-conversion of positive sputum smears at 8 weeks of treatment among new pulmonary tuberculosis patients in Kampala","author":"Nandawula","year":"2013"},{"key":"key\n\t\t\t\t20180821093403_CIT0003","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0970-2113.44122","article-title":"A study of sputum conversion in new smear positive pulmonary tuberculosis cases at the monthly intervals of 1, 2 & 3 month under directly observed treatment, short course (DOTS) regimen","volume":"25","author":"Bawri","year":"2008","journal-title":"Lung India"},{"key":"key\n\t\t\t\t20180821093403_CIT0004","first-page":"263","article-title":"Factors influencing sputum smear conversion at one and two months of tuberculosis treatment","volume":"23","author":"Pajankar","year":"2008","journal-title":"Oman Med J"},{"key":"key\n\t\t\t\t20180821093403_CIT0005","first-page":"570","article-title":"Sputum microscopy results at two and three months predict outcome of tuberculosis treatment","volume":"1","author":"Zhao","year":"1997","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0006","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(09)70042-8","article-title":"Biomarkers for tuberculosis disease activity, cure, and relapse","volume":"9","author":"Wallis","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1473-3099(10)70071-2","article-title":"Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis","volume":"10","author":"Horne","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0008","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1062","article-title":"Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months","volume":"147","author":"Mitchison","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0009","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1086\/655127","article-title":"Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy","volume":"51","author":"Fitzwater","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0010","first-page":"22","article-title":"Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it","volume":"60","author":"Parikh","year":"2012","journal-title":"J Assoc Physicians India"},{"key":"key\n\t\t\t\t20180821093403_CIT0011","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180821093403_CIT0012","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1128\/AAC.05526-11","article-title":"Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines","volume":"56","author":"McIlleron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180821093403_CIT0013","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/106002809603000901","article-title":"Low antituberculosis drug concentrations in patients with AIDS","volume":"30","author":"Peloquin","year":"1996","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180821093403_CIT0014","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1128\/AAC.02468-12","article-title":"Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients","volume":"57","author":"Burhan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180821093403_CIT0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10096-007-0454-6","article-title":"Peak plasma rifampicin level in tuberculosis patients with slow culture conversion","volume":"27","author":"Chang","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5588\/09640569513002","article-title":"Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia","volume":"6","author":"van Crevel","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"issue":"(9)","key":"key\n\t\t\t\t20180821093403_CIT0017","doi-asserted-by":"crossref","first-page":"e014679","DOI":"10.1136\/bmjopen-2016-014679","article-title":"Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study","volume":"7","author":"Sekaggya-Wiltshire","year":"2017","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180821093403_CIT0018","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10461-006-9078-6","article-title":"Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management","volume":"10","author":"Simoni","year":"2006","journal-title":"AIDS Behav"},{"key":"key\n\t\t\t\t20180821093403_CIT0019","first-page":"1172","article-title":"Anti-TB drug concentrations and drug-associated toxicities among TB\/HIV-coinfected patients","volume":"72","author":"Sekaggya-Wiltshire","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180821093403_CIT0020","author":"Monolix"},{"key":"key\n\t\t\t\t20180821093403_CIT0021","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"issue":"(1)","key":"key\n\t\t\t\t20180821093403_CIT0022","article-title":"The role of therapeutic drug monitoring in mycobacterial infections","volume":"5","author":"Peloquin","year":"2017","journal-title":"Microbiol Spectr"},{"key":"key\n\t\t\t\t20180821093403_CIT0023","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180821093403_CIT0026","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5588\/ijtld.14.0405","article-title":"Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients","volume":"19","author":"Mah","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0027","unstructured":"Sloan D . Pharmacokinetic variability in TB therapy: associations with HIV and effect on outcome. Presented at: Conference on Retroviruses and Opportunistic Infections (3\u20136 March 2014; Boston, Massachusetts); 2014."},{"key":"key\n\t\t\t\t20180821093403_CIT0028","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0029","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/jac\/dku210","article-title":"Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study","volume":"69","author":"Prahl","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"(6)","key":"key\n\t\t\t\t20180821093403_CIT0030","article-title":"Population pharmacokinetics of pyrazinamide in patients with tuberculosis","volume":"61","author":"Alsultan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180821093403_CIT0031","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0032","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1093\/cid\/cix158","article-title":"Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis","volume":"64","author":"Rockwood","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180821093403_CIT0033","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.03931-14","article-title":"Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis","volume":"59","author":"Chigutsa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180821093403_CIT0034","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/AAC.00756-15","article-title":"Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis","volume":"59","author":"Sturkenboom","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180821093403_CIT0035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00228-016-2083-4","article-title":"Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring","volume":"72","author":"Verbeeck","year":"2016","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/5\/708\/25520998\/ciy179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T23:04:05Z","timestamp":1570835045000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/5\/708\/4919550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,3]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,3,3]]},"published-print":{"date-parts":[[2018,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy179","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9,1]]},"published":{"date-parts":[[2018,3,3]]}}}